Healio

Kite seeks expanded approval of Yescarta for large B-cell lymphoma

Kite Pharma submitted a supplemental biologics license application to the FDA that seeks expanded approval of axicabtagene ciloleucel. Axicabtagene ciloleucel (Yescarta, Kite Pharma), a CD19-directed ...
Pharmabiz

Kite's CAR T cell therapy Yescarta gets US FDA nod to treat adults with certain types of large B-cell lymphoma

Kite, a Gilead Company, has announced that the US Food and Drug Administration (FDA) has granted regular approval to Yescarta (axicabtagene ciloleucel), the first chimeric antigen receptor T cell (CAR ...
Business Wire

Kite Submits Supplemental Biologics License Application to U.S. Food and Drug Administration for Earlier Use of Yescarta ® in Large B-cell Lymphoma

SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), today announced that it has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug ...
Business Wire

Kite’s Yescarta™ (Axicabtagene Ciloleucel) Becomes First CAR T Therapy Approved by the FDA for the Treatment of Adult Patients With Relapsed or Refractory Large B-Cell ...

FOSTER CITY, Calif. & SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company, (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has granted regular approval to ...